Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 4/20 | 0.46 |
| ▸ | CSGALNACT1 | Q8TDX6 | 1/20 | 0.46 |
| ▸ | DHODH | Q02127 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | GRN | P28799 | 2/20 | 0.38 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 3/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | HPGDS | O60760 | 1/20 | 0.37 |
| ▸ | GCGR | P47871 | 3/20 | 0.37 |
| ▸ | CFTR | P13569 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1761762 | 0.98 | DGAT1 (0.47) | DGAT1CSGALNACT1DHODHTP53GRN | |
| Trifluoroacetic Acid SCHEMBL1761467 | 0.92 | DGAT1 (0.45) | DGAT1CSGALNACT1DHODHPTGDR2CFTR | |
| Trifluoroacetic Acid SCHEMBL1761834 | 0.91 | DGAT1 (0.44) | DGAT1CSGALNACT1DHODHPTGDR2CA2 | |
| Trifluoroacetic Acid SCHEMBL1761322 | 0.90 | MAPK14 (0.40) | DGAT1CSGALNACT1TP53GRNSORT1 | |
| SCHEMBL1762132 | 0.89 | DGAT1 (0.47) | DGAT1CSGALNACT1DHODHPTGDR2CFTR | |
| SCHEMBL1761831 | 0.88 | DGAT1 (0.41) | DGAT1CSGALNACT1DHODHHPGDSGCGR | |
| SCHEMBL1761764 | 0.88 | DGAT1 (0.46) | DGAT1CSGALNACT1DHODHPTGDR2CFTR | |
| SCHEMBL13249246 | 0.88 | DGAT1 (0.46) | DGAT1CSGALNACT1DHODHGRNSORT1 | |
| SCHEMBL1761805 | 0.88 | MAPK14 (0.41) | DGAT1CSGALNACT1TP53GRNSORT1 | |
| Trifluoroacetic Acid SCHEMBL1761527 | 0.88 | DGAT1 (0.41) | DGAT1CSGALNACT1DHODHGRNSORT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118302-A1 | PREPARATION AND USE OF BIPHENYL-4-YL-CARBONYLAMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER PHARMACEUTICALS CORPORATION (US) | 2011-05-19 | — | — | US | disclosed |
| EP-1805156-B1 | PREPARATION AND USE OF BIPHENYL-4-YL-CARBONYLAMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER HEALTHCARE LLC (US) | 2010-12-22 | — | — | EP | disclosed |
| US-7759376-B2 | Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity | BAYER HEALTHCARE LLC (US) | 2010-07-20 | — | — | US | disclosed |
| US-20070265298-A1 | Preparation and Use of Biphenyl-4-Yl-Carbonylamino Acid Derivatives for the Treatment of Obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265298-A1 | Preparation and Use of Biphenyl-4-Yl-Carbonylamino Acid Derivatives for the Treatment of Obesity | FABP4, GPR119, PGC | DGAT1 486/4885CSGALNACT1 3157/4885DHODH 2149/4885 |
| US-20110118302-A1 | PREPARATION AND USE OF BIPHENYL-4-YL-CARBONYLAMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | FABP4, GPR119, PGC | DGAT1 486/4885CSGALNACT1 3157/4885DHODH 2149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.